![nonmem accp nonmem accp](https://docplayer.net/docs-images/82/85468918/images/10-0.jpg)
Any patient with an intrinsic coagulation disorder (defined as pretreatment abnormalities in their international normalized ratios (INR)> 1.2 or activated partial thromboplastin time (APTT)> 85 s), or recent childbirth was excluded from the study. Seventy-two ml min −1 was chosen, as it is similar to the cut-off point for normal renal function used in studies for other renally cleared drugs. Patients were also required to have normal values of bilirubin, albumin, and an estimated glomerular filtration rate ≥ 72 ml min −1 according to the method of Cockcroft and Gault, but where lean body weight was used instead of total body weight. Patients considered for inclusion were required to have normal hepatic enzyme concentrations defined by values of liver enzymes within twice the normal range (defined by the pathology department at the study institution). Those receiving prophylactic doses were prescribed 4000 IU (40 mg) once daily. The investigators did not influence dose in any way, with patients receiving 100 IU kg −1 (1 mg kg −1) of enoxaparin twice daily for the treatment of ACS or DVT. The patients were typical of those normally receiving enoxaparin, as these conditions are routinely managed as in-patients in the study institution. Patients admitted to the Royal Brisbane Hospital, a tertiary referral hospital, and prescribed enoxaparin as part of normal clinical care for the treatment of acute coronary syndrome (ACS), deep vein thrombosis (DVT) or prophylaxis of these conditions were eligible for entry into the study.
![nonmem accp nonmem accp](https://cyberleninka.org/viewer_images/72306/f/1.png)
We therefore aimed to identify a suitable dosing regimen for enoxaparin in obese patients, using a population pharmacokinetic–pharmacodynamic modelling approach. Because of these factors, it has not been possible to extrapolate these findings to the typical patient requiring management with enoxaparin. The weight descriptor used to dose enoxaparin was not provided. This study was carried out in healthy volunteers given a dose of 150 IU kg −1, and the authors suggested no dose adjustment was required for obese individuals. To date, we are aware of one other study of enoxaparin in obese individuals. Accurate dosing of low molecular weight heparins (LMWHs) is of significant clinical importance, to ensure efficacy and minimize the risk of adverse bruising or more severe bleeding events. However, to date, little dosing information has been presented in the literature for this subpopulation. It follows that many patients requiring medical intervention with enoxaparin for cardiovascular disease or thromboembolic disorders are obese.
![nonmem accp nonmem accp](https://0.academia-photos.com/attachment_thumbnails/36906944/mini_magick20190306-23810-l9c2g3.png)
The prevalence of obesity is increasing in adults, as well as children, with less physical activity, more sedentary occupations and a greater use of automation to complete simple tasks considered as possible contributing factors. Please stop back for periodic updates from the Planning Committee.Obesity is a world-wide health problem that is highly correlated with morbidity and mortality from cardiovascular disease, diabetes, osteoarthritis and depression. The main conference will leverage and build on our experience with virtual ACoP11 and feature numerous exciting scientific sessions, poster presentations, awards, SIG events, dedicated activities for students and trainees, as well as ample networking opportunities. It also embraces the pillars of our 5-year strategic plan: Scientific Expertise and Innovation, Influence, Education, Tools and Resources, and Internationalization.ĪCoP12 will host a pre-conference event titled “ Integrating Standardization and Innovation in Your Organization: Find a Workflow that Works for You!”.
![nonmem accp nonmem accp](https://slideplayer.com/slide/4538791/15/images/3/Introduction+to+NONMEM.jpg)
Our theme aligns with ISoP’s vision to promote and advance the discipline of Pharmacometrics and broaden its impact. As we chart a course for the future of Pharmacometrics, we also honor the many scientific pioneers who made this discipline what it is today. The theme of ACoP12 is “ Charting the Course for Our Future”. This change in conference format also allows us to better support our global Pharmacometrics community with a diverse speaker roster and more opportunities for international participation. Although we are seeing progress in the availability of vaccines worldwide, given the ongoing uncertainties in travel and evolving restrictions around meeting sizes and mask requirements, the ISoP Board of Directors decided that holding an in-person meeting is not optimal this year. On behalf of the Planning Committee, I cordially invite you to attend the Twelfth American Conference on Pharmacometrics (ACoP12), which will now be hosted virtually from November 8-12, 2021.